Repeated failures with treatment trials based on amyloid and tau hypothesis have made researchers’ interest turn to other strategies such as cell replacement or immune regulation.The accumulation of misfolded proteins like beta-amyloid and tau triggers microglial activation and leads to neuronal inf

After repeated disappointments with amyloid-targeting agents in Alzheimer’s disease (AD), attention in AD research has in part turned to tau. Moreover, efforts are being made to target amyloid and tau at the same time for the treatment of AD.BeyondBio, headquartered in Daejeon, a Korean biopharmaceu

ISU ABXIS (KOSDAQ: 086890), headquartered in Seongnam, a Korean biotechnology company developing new and novel bio-therapeutics to treat cancers and neurodegenerative diseases such as Alzheimer’s disease (AD), announced on November 19th that the research data on the discovery of first-in-class antib

GLP-1 agonists have been attracting attention as a new neuroprotective therapeutic strategy for Parkinson's disease (PD).Exenatide, a GLP-1 (Glucagon-like Peptide-1) receptor agonist, was originally developed as a diabetes medication and is an example of the promise of drug repurposing or reposi

Kainos Medicine (hereafter Kainos for short), a clinical-stage biotech company headquartered in Seongnam, South Korea, specializing in the research and development of innovative medicines for brain diseases, cancers and infectious diseases, announced on November 16th that the U.S. Food and Drug Admi

Ensol Biosciences (hereafter Ensol for short) is developing the ‘Moriah1000 (M1K)’, a candidate drug for the treatment of Alzheimer's disease (AD). M1K, a synthetic peptide, binds the Receptor for Advanced Glycation Endproducts (RAGE) that is over-expressed in the AD brains, serves as a receptor

Dysregulated inflammasomes are associated with an enormous number of autoimmune and inflammatory disorders including Alzheimer’s disease. Inflammasomes are intracellular multi-protein complex in the innate immune system. Activated inflammasomes produce highly pro-inflammatory cytokines and induce th

Accumulating evidence suggests that the most common neurodegenerative disorders, Alzheimer’s and Parkinson’s diseases, share neuroinflammation mediated by microglia and astrocytes in common in the progression of diseases. Beta-amyloid fibrils in Alzheimer’s disease (AD) induce the activation of micr

The most recognized hypotheses on the pathogenic mechanisms of Alzheimer’s disease (AD) are the amyloid cascade hypothesis and the tau hyperphosphorylation hypothesis. However, the underlying causes and optimal treatment are still elusive. With the repeated failure of clinical trials based on the am

This year the CTAD ‘Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research’ was awarded to Ronald Petersen, MD, Ph.D., at Mayo Clinic, Rochester, in recognition for his extensive contributions to the advancement of AD clinical trials.Dr. Ronald C. Petersen received a Ph.D. from t

AriBio will present the topline results of AR1001 against Alzheimer’s disease, titled ‘Results of a Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Disease Patients’ on November 10th, at the 14th annual Clinical Trials on Alzheimer's Disease (CTAD) conference being held in Boston.AR1001

PeopleBio announced on November 9th that it has signed a contract with Singapore's All Eights to supply a total of $1.7 million worth of Alzheimer's screening kits for three years.This contract starts from the day the product is registered at the Singapore Health Science Authority, which usu

On November 8th, Neurophet announced that it has successfully raised $16 million in a round of Series B funding from 7 domestic inventors. SBI Investment Korea, Kolon Investment, The Wells Investment, ES Investor, Future play, Profit Asset Management, and J Curve Investment participated in this Seri

Exosomes are nanoscale and lipid-layered extracellular vesicles, commonly found in the fluids and tissue of the brain. They carry specific proteins, lipids, and RNAs, and play key roles in intercellular communications.The roles of exosomes in Alzheimer’s disease (AD) are somewhat controversial. Exos

Approximately a third of Alzheimer patients were found to be non-compliant with oral donepezil, resulting in large fluctuations in blood drug level and the occurrence of adverse effects like nausea and vomiting. The injectable depot of donepezil that has the advantages of less dosing frequency, less

BIORCHESTRA, a South Korean bio-venture pioneering the development of RNA therapeutics, announced on November 5th that the company will present the research data at the 14th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in Boston on November 9-12, 2021.The company w

Neuracle Science, a Seoul-based biopharmaceutical developing neuropeptides and antibody therapeutics to treat neurodegenerative diseases, announced on October 28th that the Clinical Trial Application (CTA) of NS101 phase 1 was approved.The CTA was submitted to the Health Canada in September 2021. Th

On November 5th, the Ministry of Food and Drug Safety of South Korea approved the Icure’s ‘Donepezil Transdermal Patch’, about seven months after applying for permission in April. With this approval, Icure won the title of the world's first successful commercialization of donepezil patch.Icure,

A healthy brain has an internal rhythm of 40-Hertz. But Alzheimer’s brains have lower frequency pattern compared to healthy brains of the same age. If so, can brain stimulation with 40-Hz external sound vibration restore cognitive function in Alzheimer’s patients?In a pilot study in 2016, researcher

The development of a next-generation diagnostic platform that simply diagnoses Alzheimer's disease through the retina of the eye is expected to start soon.Current validated biomarkers like PET scan and CSF study are not broadly available due to cost and invasiveness. Several blood-based approach